GSA Capital Partners LLP Takes $1.19 Million Position in Disc Medicine, Inc. $IRON

Key Points

• GSA Capital Partners acquired 16,324 shares of Disc Medicine worth approximately $1.19 million in the second quarter. Institutional investors own 83.7% of the company, with several other funds also initiating or increasing positions.
• Analyst sentiment is broadly positive: 10 analysts rate the stock a Buy, one rates it Hold and one rates it Sell. The consensus rating is “Moderate Buy”, with an average price target of $106.50.
• Disc Medicine shares opened at $80.05, compared with a 12-month range of $40.00 to $99.50. The company beat quarterly EPS estimates, reporting a loss of $1.54 per share versus the expected loss of $1.71, although insiders have sold more than $8 million of stock over the past 90 days.

GSA Capital Partners LLP acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 16,324 shares of the company's stock, valued at approximately $1,194,000.

Several other institutional investors also recently modified their holdings of the stock. Handelsbanken Fonder AB bought a new stake in Disc Medicine during the second quarter valued at approximately $929,000. Seven Fleet Capital Management LP bought a new position in shares of Disc Medicine in the 1st quarter worth $207,000. Bank of America Corp DE raised its position in shares of Disc Medicine by 22.6% during the 1st quarter. Bank of America Corp DE now owns 166,775 shares of the company's stock valued at $10,664,000 after buying an additional 30,789 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Disc Medicine by 47.8% during the 1st quarter. California State Teachers Retirement System now owns 34,382 shares of the company's stock valued at $2,198,000 after buying an additional 11,126 shares in the last quarter. Finally, SummitTX Capital L.P. purchased a new stake in shares of Disc Medicine during the 1st quarter valued at $884,000. 83.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IRON has been the subject of several research reports. Morgan Stanley reiterated an "overweight" rating and issued a $90.00 target price on shares of Disc Medicine in a research report on Monday. HC Wainwright raised their price target on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Wedbush reaffirmed an "outperform" rating and set a $88.00 price target on shares of Disc Medicine in a research note on Wednesday, June 10th. Wall Street Zen upgraded Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Disc Medicine in a research report on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $106.50.

Disc Medicine Stock Performance

NASDAQ IRON opened at $80.05 on Tuesday. The company has a 50-day simple moving average of $74.89 and a two-hundred day simple moving average of $69.89. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The firm has a market cap of $306.59 million, a price-to-earnings ratio of -12.17 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, equities analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Insider Transactions at Disc Medicine

In related news, COO Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the transaction, the chief operating officer directly owned 54,324 shares of the company's stock, valued at $3,758,677.56. The trade was a 25.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John D. Quisel sold 34,000 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer directly owned 226,064 shares of the company's stock, valued at $15,871,953.44. The trade was a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 111,516 shares of company stock worth $8,063,979. Insiders own 3.76% of the company's stock.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source